Literature DB >> 28428206

Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

C McNamara1, G Sugrue1, B Murray2, P J MacMahon3.   

Abstract

An understanding of the new generation of MS drugs in conjunction with the key role MR imaging plays in the detection of disease progression, opportunistic infections, and drug-related adverse effects is of vital importance to the neuroradiologist. Part 1 of this review outlined the current treatment options available for MS and examined the mechanisms of action of the various medications. It also covered specific complications associated with each form of therapy. Part 2, in turn deals with the subject of pharmacovigilance and the optimal frequency of MRI monitoring for each individual patient, depending on his or her unique risk profile. Special attention is given to the diagnosing of progressive multifocal leukoencephalopathy in patients treated with natalizumab as this is a key area in which neuroradiologists can contribute to improved patient outcomes. This article also outlines the aims of treatment and reviews the possibility of "no evidence of disease activity" becoming a treatment goal with the availability of more effective therapies. Potential future areas and technologies including image subtraction, brain volume measurement and advanced imaging techniques such as double inversion recovery are also reviewed. It is anticipated that such advancements in this rapidly developing field will improve the accuracy of monitoring an individual patient's response to treatment.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28428206      PMCID: PMC7963720          DOI: 10.3174/ajnr.A5148

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  101 in total

1.  Diffusion tensor imaging applications in multiple sclerosis patients using 3T magnetic resonance: a preliminary study.

Authors:  Lorenzo Testaverde; Laura Caporali; Eugenio Venditti; Giovanni Grillea; Claudio Colonnese
Journal:  Eur Radiol       Date:  2011-12-09       Impact factor: 5.315

Review 2.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

3.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

Review 4.  Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Authors:  Angela Vidal-Jordana; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

5.  Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions.

Authors:  M P Wattjes; G G Lutterbey; J Gieseke; F Träber; L Klotz; S Schmidt; H H Schild
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

6.  The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.

Authors:  M Magraner; F Coret; B Casanova
Journal:  Eur J Radiol       Date:  2012-03-04       Impact factor: 3.528

7.  Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole.

Authors:  R T Naismith; J Xu; N T Tutlam; P T Scully; K Trinkaus; A Z Snyder; S-K Song; A H Cross
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

8.  Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Authors:  Ernst-Wilhelm Radue; Paul O'Connor; Chris H Polman; Reinhard Hohlfeld; Peter Calabresi; Krystof Selmaj; Nicole Mueller-Lenke; Catherine Agoropoulou; Frederick Holdbrook; Ana de Vera; Lixin Zhang-Auberson; Gordon Francis; Pascale Burtin; Ludwig Kappos
Journal:  Arch Neurol       Date:  2012-10

9.  Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Authors:  Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick
Journal:  Ann Neurol       Date:  2013-01       Impact factor: 10.422

Review 10.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21
View more
  2 in total

1.  Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.

Authors:  Chiara Tremolanti; Chiara Cavallini; Laurence Meyer; Christian Klein; Eleonora Da Pozzo; Barbara Costa; Lorenzo Germelli; Sabrina Taliani; Christine Patte-Mensah; Ayikoé-Guy Mensah-Nyagan
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.590

2.  Depletion of PD-1-positive cells ameliorates autoimmune disease.

Authors:  Peng Zhao; Peng Wang; Shuyun Dong; Zemin Zhou; Yanguang Cao; Hideo Yagita; Xiao He; Song Guo Zheng; Simon J Fisher; Robert S Fujinami; Mingnan Chen
Journal:  Nat Biomed Eng       Date:  2019-03-04       Impact factor: 29.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.